ENB Therapeutics
  • Home
  • About
  • Pipeline
  • News/Blog
  • Contact Us
Select Page

ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023

by admin | Nov 9, 2023 | Press Releases

ENB-003 in combination with KEYTRUDA® (pembrolizumab) demonstrated encouraging objective responses, disease control and progression-free survival in patients with metastatic platinum refractory/resistant ovarian cancer (PROC) Encouraging results support further...

Recent Posts

  • Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics’ ENB-003 for the Treatment of Ovarian Cancer
  • ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023
  • ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023
  • ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy
  • ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer

Archives

  • May 2024
  • November 2023
  • July 2023
  • November 2022
  • May 2022
  • February 2021
  • November 2020
  • February 2019
  • September 2018
  • April 2016
  • January 2016
  • June 2015

Categories

  • Press Releases
  • Uncategorized

Explore

  • Home
  • About
  • Pipeline
  • News/Blog
  • Contact Us

Recent Posts

Click Here

ENB Therapeutics
Alexandria Center For Life Sciences,
Launch Labs
430 E 29th Street, 14th Floor
New York, NY 10016
(212) 792-2317
info@enbpharma.com

Designed by Visual Fuel Design